Literature DB >> 10689316

Superantigens - powerful modifiers of the immune system.

J Fraser1, V Arcus, P Kong, E Baker, T Proft.   

Abstract

Superantigens are powerful microbial toxins that activate the immune system by binding to class II major histocompatibility complex and T-cell receptor molecules. They cause a number of diseases characterized by fever and shock and are important virulence factors for two human commensal organisms, Staphylococcus aureus and Streptococcus pyogenes, as well as for some viruses. Their mode of action and variation around the common theme of over-stimulating T cells, provides a rich insight into the constant battle between microbes and the immune system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10689316     DOI: 10.1016/s1357-4310(99)01657-3

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  38 in total

1.  Preparation and activity of conjugate of monoclonal antibody HAb18 against hepatoma F(ab')(2) fragment and staphylococcal enterotoxin A.

Authors:  L J Yang; Y F Sui; Z N Chen
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Recruitment and in situ renewal regulate rapid accumulation of CD11c+ cells in the lung following intranasal superantigen challenge.

Authors:  Guruprasaadh Muralimohan; Robert J Rossi; Anthony T Vella
Journal:  Int Arch Allergy Immunol       Date:  2008-05-02       Impact factor: 2.749

3.  Passive therapy with humanized anti-staphylococcal enterotoxin B antibodies attenuates systemic inflammatory response and protects from lethal pneumonia caused by staphylococcal enterotoxin B-producing Staphylococcus aureus.

Authors:  Melissa J Karau; Mulualem E Tilahun; Ashton Krogman; Barbara A Osborne; Richard A Goldsby; Chella S David; Jayawant N Mandrekar; Robin Patel; Govindarajan Rajagopalan
Journal:  Virulence       Date:  2016-12-07       Impact factor: 5.882

4.  Superantigen-induced CD4 memory T cell anergy. I. Staphylococcal enterotoxin B induces Fyn-mediated negative signaling.

Authors:  Andrew R O Watson; David K Janik; William T Lee
Journal:  Cell Immunol       Date:  2012-02-17       Impact factor: 4.868

5.  A role for IFNgamma in differential superantigen stimulation of conventional versus plasmacytoid DCs.

Authors:  Guruprasaadh Muralimohan; Anthony T Vella
Journal:  Cell Immunol       Date:  2006-10-11       Impact factor: 4.868

6.  Characterization of two novel pyrogenic toxin superantigens made by an acute rheumatic fever clone of Streptococcus pyogenes associated with multiple disease outbreaks.

Authors:  Laura M Smoot; John K McCormick; James C Smoot; Nancy P Hoe; Ian Strickland; Robert L Cole; Kent D Barbian; Cathleen A Earhart; Douglas H Ohlendorf; L George Veasy; Harry R Hill; Donald Y M Leung; Patrick M Schlievert; James M Musser
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

7.  Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination.

Authors:  Ross D LeClaire; Robert E Hunt; Sina Bavari
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

8.  Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.

Authors:  Garry L Morefield; Lynn D Hawkins; Sally T Ishizaka; Teri L Kissner; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

9.  Endothelial cells promote human immunodeficiency virus replication in nondividing memory T cells via Nef-, Vpr-, and T-cell receptor-dependent activation of NFAT.

Authors:  Jaehyuk Choi; Jason Walker; Kristina Talbert-Slagle; Paulette Wright; Jordan S Pober; Louis Alexander
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Expression, purification and crystallization of Streptococcus dysgalactiae-derived mitogen.

Authors:  Anastassios C Papageorgiou; Susanna Saarinen; Rosa Ramirez-Bartutis; Hidehito Kato; Takehiko Uchiyama; Teruo Kirikae; Toru Miyoshi-Akiyama
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.